

NEUVIOR

Net Zero Commitment 2045

A public company-wide commitment for NEUVIOR Pharmaceuticals Ltd, prepared to support NHS-facing sustainability expectations and the wider transition to a lower-carbon operating model.

Legal entity	NEUVIOR Pharmaceuticals Ltd
Company number	SC857853
Issue date	10 April 2026
Review date	10 April 2027
Headquarters	Clyde Offices, 2nd Floor, 48 West George Street, Glasgow, Scotland, G2 1BP
Applies to	NEUVIOR Pharmaceuticals Ltd and all operations under its operational control

Why this document exists

This public document sets out NEUVIOR's climate commitment and the operational measures being taken to reduce emissions over time in a way that is proportionate to a UK-based, early-stage digital health company building the PHARMORIS platform.

1. Commitment statement

Public commitment

NEUVIOR Pharmaceuticals Ltd commits to achieve net zero greenhouse gas emissions by 2045 across Scope 1, Scope 2 and all relevant Scope 3 emissions for the company. This commitment applies to the whole business as it exists today and will extend to future operations as the company grows. The company will prioritise absolute emissions reduction over offsetting, will align its reporting to the GHG Protocol, and will review this commitment at least annually.

NEUVIOR has chosen a 2045 target because NHS England's supplier guidance and the Evergreen Sustainable Supplier Assessment position 2045 as the direction of travel for suppliers that want to align with NHS net zero ambitions beyond the minimum 2050 threshold. The commitment is therefore intentionally more ambitious than the minimum procurement baseline and is designed to support future NHS, investor and partner scrutiny.

2. What this commitment covers

This commitment covers the legal entity named above and all activities under its operational control. NEUVIOR is currently a UK-based, early-stage digital health company. Its current operations are centred on research, product development, software engineering, product design, data analysis, founder-led business development, governance, and corporate administration associated with the PHARMORIS platform.

The commitment covers:

- Scope 1 emissions from any direct fuel combustion, refrigerants, or company-controlled vehicles that may arise.
- Scope 2 emissions from purchased electricity, steam, heating or cooling for any premises directly controlled by NEUVIOR.
- All relevant Scope 3 emissions, including at minimum the categories specifically referenced by NHS procurement and Evergreen guidance, and wider value-chain categories as the company's reporting matures.

3. How NEUVIOR will get there

- Measure first, then reduce. NEUVIOR will complete and publish a company-wide greenhouse gas inventory and update it annually.
- Reduce at source. The company will focus first on direct operational reductions rather than on credits or offsets.
- Design for a low-carbon operating model. Because PHARMORIS is a digital product, the main operational levers are cloud and software efficiency, hardware and services procurement, travel, commuting patterns, workspace energy, and waste.
- Build supplier discipline early. NEUVIOR will increasingly screen material suppliers for sustainability and modern-slavery readiness as the company scales.

- Use neutralisation only for true residual emissions. Any later use of neutralisation will sit behind robust reduction efforts and will not replace operational decarbonisation.

Priority area	Immediate commitment
Inventory and reporting	Complete the first full emissions inventory, publish it, and review it at least annually.
Cloud and digital delivery	Control unnecessary compute, data duplication and storage growth; request sustainability information from material cloud and software suppliers.
Travel	Use virtual meetings by default where practical, prefer rail and lower-carbon options over short-haul air where feasible.
Workspaces and energy	Where NEUVIOR directly controls premises or utilities, preference renewable-backed electricity and efficient equipment.
Devices and purchased goods	Extend device life where practical, prefer repairable/refurbishable equipment, and dispose of obsolete equipment responsibly.
Supply chain	Map material suppliers, add sustainability and modern-slavery screening over time, and avoid unnecessary physical distribution where digital delivery is sufficient.

4. 2026 to 2030 priority milestones

Timing	Milestone	Purpose
Q2 2026	Publish this Net Zero Commitment and the first public Carbon Reduction Plan.	Create a clear, NHS-facing base of governance and intent.
Q2-Q3 2026	Complete the first formal greenhouse gas inventory for Scope 1, Scope 2 and the relevant Scope 3 categories; publish the resulting emissions schedule.	Move from commitment-only maturity to quantified public reporting.
Q3 2026	Create a supplier register covering material cloud, software, device and professional-service suppliers, with sustainability notes where available.	Improve Scope 3 understanding and future procurement discipline.
Q4 2026	Decide the appropriate route for target-validation readiness, including whether to use the SBTi SME pathway.	Build a credible bridge toward stronger target validation later.
2027-2028	Improve data quality, review relevant Scope 3 categories beyond the minimum NHS subset, and publish annual updates.	Strengthen transparency and support higher sustainability maturity over time.
By 2030	Embed low-carbon operating practices across travel, procurement, digital infrastructure and workspaces.	Create the operating discipline needed for a credible 2045 trajectory.

5. Governance, review and approval

Responsibility for this commitment sits with the director of NEUVIOR Pharmaceuticals Ltd. The commitment will be reviewed at least annually, and sooner where there is a material change to the company structure, operating model, physical estate, or emissions profile. Future versions may be expanded to include validated targets, verified emissions, and additional public sustainability disclosures as the company matures.

Approval statement

This commitment is issued on behalf of NEUVIOR Pharmaceuticals Ltd.
 Approved for publication by: Varun Cruz, Director
 Company number: SC857853
 Issue date: 10 April 2026

Prepared with reference to

NHS England, Carbon reduction plan and net zero commitment requirements for the procurement of NHS goods, services and works (updated 11 December 2025).

NHS England, Evergreen Sustainable Supplier Assessment User Guide, April 2026.

Cabinet Office, PPN 006 Technical Standard for Completion of Carbon Reduction Plans, updated 10 July 2025.

Greenhouse Gas Protocol Corporate Standard and Corporate Value Chain (Scope 3) Standard.

Science Based Targets initiative guidance on the Corporate Net-Zero Standard and SME route.

Companies House record for NEUVIOR Pharmaceuticals Ltd (SC857853).